title: [Cisplatin and S-1 combination therapy after reduction surgery for stage IV gastric cancer].
abstract: To evaluate the efficacy of cisplatin and S-1 combination therapy after reduction surgery for Stage IV gastric cancer, we retrospectively examined 73 patients with Stage IV gastric cancer who underwent gastrectomy. We classified the patients into the following four groups according to their postoperative therapies and analyzed their outcomes: A) S-1 +CDDP therapy (n=22); B) oral 5-FU therapy (n=30); C) 5-FU+CDDP therapy (n=14); and D) S-1 therapy (n= 7). The median survival time was 465 days in the S-1+CDDP therapy group, 158 days in the oral 5-FU therapy group, 332 days in the 5-FU+CDDP therapy group, and 374 days in the S-1 therapy group. The respective 2-year and 3-year survival rate was 37.8% and 20.2% in the S-1+CDDP therapy group, 3.4% and 3.4% in the oral 5-FU therapy group, 7.1% and 0% in the 5-FU+CDDP therapy group, and 0% and 0% in the S-1 therapy group, respectively. We consider that S-1+CDDP therapy after reduction surgery improves survival in patients with Stage IV gastric cancer and should be further investigated.
authors.affiliation: Dept. of Surgery, Saint Mary Hospital.
authors.forename: Satoshi
authors.initials: S
authors.lastname: Taniwaki
authors.forename: Akihiro
authors.initials: A
authors.lastname: Saruwatari
authors.forename: Takeshi
authors.initials: T
authors.lastname: Yoshida
authors.forename: Ayako
authors.initials: A
authors.lastname: Mizoguchi
authors.forename: Yuhei
authors.initials: Y
authors.lastname: Kitasato
authors.forename: Toshiko
authors.initials: T
authors.lastname: Kitamura
authors.forename: Atsuhiro
authors.initials: A
authors.lastname: Hidaka
authors.forename: Kouji
authors.initials: K
authors.lastname: Shiota
authors.forename: Hisashi
authors.initials: H
authors.lastname: Kuroda
authors.forename: Masaya
authors.initials: M
authors.lastname: Tanaka
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Higashi
authors.forename: Yoko
authors.initials: Y
authors.lastname: Iwanaga
authors.forename: Yukiko
authors.initials: Y
authors.lastname: Ogata
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000009:adverse effects / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010094:Oxonic Acid / Q000009:adverse effects / Q000627:therapeutic use*; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology* / Q000601:surgery; D015996:Survival Rate; D005641:Tegafur / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D002945:Cisplatin